外周血生物标志物p-tau217在阿尔茨海默病中的应用前景  

Application prospect of blood-based biomarker p-tau217 in Alzheimer disease

作　　者：白丽[1] 胡卫红[1] Bai Li;Hu Weihong(The Second Geriatric Department,Shanghai Mental Health Center,Shanghai Jiao Tong University School of Medicine,Shanghai 201108,China)

机构地区：[1]上海交通大学医学院附属精神卫生中心老年二科,201108

出　　处：《神经疾病与精神卫生》2023年第11期807-813,共7页Journal of Neuroscience and Mental Health

基　　金：上海市科委2022年度“科技创新行动计划”项目(22DZ2302900)。

摘　　要：阿尔茨海默病(AD)是一种常见的老年痴呆,目前仍缺乏有效治疗方法。因此,早诊断、早干预尤为重要。目前,外周生物标志物正成为AD的研究热点。血浆p-tau217在AD早期诊断、鉴别及治疗监测和预后评估中具有重要作用,具有良好的应用前景,但需进一步确定标准化的实验室方案及最佳分界值。本文就外周生物标志物在治疗AD中的研究进展进行综述,旨在为临床应用提供依据。Alzheimer disease(AD)is a common form of elderly dementia that currently lacks effective treatment.Therefore,early diagnosis and intervention are particularly important.Currently,peripheral biomarkers are becoming a research hotspot in AD.Recent studies have shown that plasma p-tau217 plays an important role in the early diagnosis,differentiation,treatment monitoring,and prognosis evaluation of AD,and has good application prospects.However,further standardization of laboratory protocols and optimal cutoff values need to be determined.This paper reviews the above progress,aiming to provide a basis for clinical applications.

关 键 词：阿尔茨海默病 生物标志物 p-tau217 综述 

分 类 号：R749.16[医药卫生—神经病学与精神病学]